Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Mov Disord ; 20(9): 1178-84, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15895421

ABSTRACT

Previous studies show that cognitive functions are more impaired in patients with Parkinson's disease (PD) and depression than in nondepressed PD patients. We compared the cognitive effects of two types of antidepressant treatments in PD patients: fluoxetine (20 mg/day) versus repetitive transcranial magnetic stimulation (rTMS, 15 Hz, 110% above motor threshold, 10 daily sessions) of the left dorsolateral prefrontal cortex. Twenty-five patients with PD and depression were randomly assigned either to Group 1 (active rTMS and placebo medication) or to Group 2 (sham rTMS and fluoxetine). A neuropsychological battery was assessed by a rater blind to treatment arm at baseline and 2 and 8 weeks after treatment. Patients in both groups had a significant improvement of Stroop (colored words and interference card) and Hooper and Wisconsin (perseverative errors) test performances after both treatments. Furthermore, there were no adverse effects after either rTMS or fluoxetine in any neuropsychological test of the cognitive test battery. The results show that rTMS could improve some aspects of cognition in PD patients similar to that of fluoxetine. The mechanisms for this cognitive improvement are unclear, but it is in the context of mood improvement.


Subject(s)
Cognition Disorders/diagnosis , Cognition Disorders/epidemiology , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/epidemiology , Fluoxetine/therapeutic use , Parkinson Disease/epidemiology , Periodicity , Selective Serotonin Reuptake Inhibitors/therapeutic use , Transcranial Magnetic Stimulation/instrumentation , Aged , Antiparkinson Agents/therapeutic use , Double-Blind Method , Female , Functional Laterality/physiology , Humans , Levodopa/therapeutic use , Male , Neuropsychological Tests , Parkinson Disease/drug therapy , Parkinson Disease/physiopathology , Prefrontal Cortex/physiopathology , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...